SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ALNY reported Third quarter 2026 results. The stock moved -25.1% on the print.
ALNYearnings

Earnings reactions, page 9

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Total TTR net product revenues were $1,149,959 thousand, representing 59% growth compared to Q3 2025.
  • Total Rare net product revenues were $141,987 thousand, representing 12% growth compared to Q3 2025.
  • GAAP Net income was $2,167,335 thousand for the third quarter of 2026.
  • Non-GAAP Net income was $2,241,910 thousand for the third quarter of 2026.
  • GAAP Income from operations was $345,798 thousand, while Non-GAAP Income from operations was $424,916 thousand.

Guidance

  • Total TTR net product revenues: $4,200 million - $4,500 million
  • Total Rare net product revenues: $500 million - $600 million
  • Total net product revenues: $4,700 million - $5,100 million
  • Net revenues from collaborations and royalties: $575 million - $625 million
  • Non-GAAP R&D and SG&A expenses: $2,700 million - $2,800 million

Notes

During the three months ended September 30, 2026, the company recorded a benefit from income taxes of $1.9 billion, primarily related to the release of valuation allowances on certain U.S. federal and state deferred tax assets.

Price and volatility reaction

The stock moved -25.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +69.0 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release232.42026-10-28
Close after release1742026-10-29
Realised move-25.1%close to close
30d ATM IV change+69.0 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →